GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BeiGene Ltd (HKSE:06160) » Definitions » Price-to-Tangible-Book

BeiGene (HKSE:06160) Price-to-Tangible-Book : 5.68 (As of Dec. 14, 2024)


View and export this data going back to 2018. Start your Free Trial

What is BeiGene Price-to-Tangible-Book?

As of today (2024-12-14), BeiGene's share price is HK$108.40. BeiGene's Tangible Book per Share of Sep. 2024 for the quarter that ended in Sep. 2024 was HK$19.09. Hence, BeiGene's Price to Tangible Book Ratio of today is 5.68.

The historical rank and industry rank for BeiGene's Price-to-Tangible-Book or its related term are showing as below:

HKSE:06160' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 3.03   Med: 5.35   Max: 11.24
Current: 5.68

During the past 11 years, BeiGene's highest Price to Tangible Book Ratio was 11.24. The lowest was 3.03. And the median was 5.35.

HKSE:06160's Price-to-Tangible-Book is ranked worse than
73.94% of 1205 companies
in the Biotechnology industry
Industry Median: 2.81 vs HKSE:06160: 5.68

A closely related ratio is called PB Ratio. As of today, BeiGene's share price is HK$108.40. BeiGene's Book Value per Sharefor the quarter that ended in Sep. 2024 was HK$19.39. Hence, BeiGene's P/B Ratio of today is 5.59.


BeiGene Price-to-Tangible-Book Historical Data

The historical data trend for BeiGene's Price-to-Tangible-Book can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BeiGene Price-to-Tangible-Book Chart

BeiGene Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Tangible-Book
Get a 7-Day Free Trial Premium Member Only Premium Member Only 11.29 6.35 4.57 5.45 5.57

BeiGene Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Price-to-Tangible-Book Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.01 5.57 5.00 4.58 7.58

Competitive Comparison of BeiGene's Price-to-Tangible-Book

For the Biotechnology subindustry, BeiGene's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BeiGene's Price-to-Tangible-Book Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BeiGene's Price-to-Tangible-Book distribution charts can be found below:

* The bar in red indicates where BeiGene's Price-to-Tangible-Book falls into.



BeiGene Price-to-Tangible-Book Calculation

BeiGene's price-to-tangible-book ratio for today is calculated as:

Price to Tangible Book=Share Price/Tangible Book per Share (Q: Sep. 2024 )
=108.40/19.088
=5.68

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.


BeiGene Price-to-Tangible-Book Related Terms

Thank you for viewing the detailed overview of BeiGene's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.


BeiGene Business Description

Address
c/o Mourant Governance Services (Cayman) Limited, 94 Solaris Avenue, Camana Bay, Grand Cayman, CYM, KY1-1108
Founded in 2010 in Beijing and having listed on the Hong Kong exchange in 2018, BeiGene is a commercial-stage biotechnology company with global sales. It focuses on oncology therapeutics and differentiates itself from other companies with a contract research organization-free, or CRO-free strategy. BeiGene runs global clinical trials with its own team. As of 2023, its core drug is Brukinsa, a small molecule drug for various blood cancers that makes up more than 50% of BeiGene's revenue.
Executives
Oyler John Victor 2101 Beneficial owner
Jpmorgan Chase & Co. 2502 Approved lending agent
The Capital Group Companies, Inc. 2201 Interest of corporation controlled by you
Baker Felix James 2201 Interest of corporation controlled by you
Baker Julian Charles 2201 Interest of corporation controlled by you
Baker Bros. Advisors (gp) Llc 2201 Interest of corporation controlled by you
Baker Brothers Life Sciences Capital, L.p. 2201 Interest of corporation controlled by you
Hhlr Advisors, Ltd. 2102 Investment manager
Hhlr Fund, L.p. 2101 Beneficial owner
Amgen Inc. 2101 Beneficial owner
Hillhouse Capital Advisors, Ltd. 2102 Investment manager
Gaoling Fund, L.p. 2101 Beneficial owner
Fidelity Management & Research Company
Fmr Co., Inc.

BeiGene Headlines

No Headlines